Новость: Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday. The U.S. Food and Drug Administration said it was informing healthcare providers of the increased rate of major adverse cardiac events observed in patients receiving Absorb in the study. The agency said it will continue to monitor Absorb's performance in clinical studies and reports submitted to it. Источник By Bill Berkrot | WASHINGTON: reuters.com/article/us-heart-abbott-stent-idUSKBN16P0IV?type=companyNews